UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

The Lancet (British edition), 2008-08, Vol.372 (9640), p.719-727

2008

Link zum Volltext

Verfügbarkeit prüfen

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Breast cancer research : BCR, 2020-08, Vol.22 (1), p.89-89, Article 89

2020

Link zum Volltext

Verfügbarkeit prüfen

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

OncoTargets and therapy, 2016-01, Vol.9 (Issue 1), p.203-210

2016

Link zum Volltext

Verfügbarkeit prüfen

PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (6), p.2064-2069

2008

Link zum Volltext

Verfügbarkeit prüfen

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy

Muscle & nerve, 2010-04, Vol.41 (4), p.500-510

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT

Clinical cancer research, 2014-07, Vol.20 (13), p.3507-3520

2014

Link zum Volltext

Verfügbarkeit prüfen

Challenges in the clinical development of PI3K inhibitors

Annals of the New York Academy of Sciences, 2013-03, Vol.1280 (1), p.19-23

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers

Journal of clinical pharmacology, 2007-04, Vol.47 (4), p.430-444

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation

Clinical pharmacology in drug development, 2016-07, Vol.5 (4), p.296-305

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Clinical cancer research, 2014-04, Vol.20 (7), p.1935-1945

2014

Link zum Volltext

Verfügbarkeit prüfen

Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

American journal of respiratory and critical care medicine, 2010-11, Vol.182 (10), p.1262-1272

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3825-3825

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4698: Combination of ceritinib (LDK378) with PI3K inhibitors (buparlisib [BKM120] and alpelisib [BYL719]) demonstrates synergistic preclinical antitumor activity in ALK-rearranged non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4698-4698

2015

Link zum Volltext

Verfügbarkeit prüfen

Some practical considerations for phase III studies with biomarker evaluations

Journal of clinical oncology, 2014-03, Vol.32 (8), p.854-855

2014

Link zum Volltext

Verfügbarkeit prüfen

BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6045-6045

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT010-CT010

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4150-4150

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract A26: Detecting PIK3CA mutations in circulating cell-free DNA from patients with metastatic cancer: An exploratory analysis in patients with endometrial and lung cancer

Molecular cancer therapeutics, 2015-07, Vol.14 (7_Supplement), p.A26-A26

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-A05: Profiling cell free DNA in breast cancer and non-small cell lung cancer using broad NGS assessment

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.LB-A05-LB-A05

2015

Link zum Volltext

Verfügbarkeit prüfen

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1038-1038

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT

Challenges in the clinical development of PI3K inhibitors

Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

PTC124 targets genetic disorders caused by nonsense mutations

Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models

Abstract 4698: Combination of ceritinib (LDK378) with PI3K inhibitors (buparlisib [BKM120] and alpelisib [BYL719]) demonstrates synergistic preclinical antitumor activity in ALK-rearranged non-small cell lung cancer (NSCLC)

Some practical considerations for phase III studies with biomarker evaluations

BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC)

Abstract CT010: Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

Abstract A26: Detecting PIK3CA mutations in circulating cell-free DNA from patients with metastatic cancer: An exploratory analysis in patients with endometrial and lung cancer

Abstract LB-A05: Profiling cell free DNA in breast cancer and non-small cell lung cancer using broad NGS assessment

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Suchergebnisse filtern